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The phenomenon of aerobic glycolysis observed in cancer cells has remained unexplained. In the
May 2007 issue of Cancer Cell, Zhang and colleagues determine that the hypoxia-inducible factor
family of transcriptional factors regulate mitochondrial biogenesis through inhibition of C-MYC.Otto Warburg was the first to describe
the phenomena of aerobic glycolysis,
whereby cancer cells are reliant on gly-
colysis, rather than the more efficient
process of oxidative phosphorylation,
for ATP production. For this discovery,
Warburg was awarded the Nobel Prize
in Physiology in 1931. Warburg be-
lieved that the metabolic disturbance
he observed was central to the pro-
cess of tumorigenesis and, in fact,
the origin of tumor cells. He hypothe-
sized that cancer developed in a two-
step process; first the irreversible
injury to respiration, which is then fol-
lowed by an increase in fermentation.
Over 80 years after this initial finding,
the molecular mechanisms respon-
sible for the metabolic switch are
ardently debated as the molecular ba-
sis of aerobic glycolysis has remained
largely unexplained.
Recent evidence regarding the mo-
lecular mechanism of the Warburg ef-
fect has come to light with the study
of clear cell renal cell carcinoma
(CC-RCC). An estimated 60%–80%
of CC-RCC can be attributed to the
mutation of the von Hippel-Lindau
(VHL) tumor suppressor gene. Recent
studies have suggested VHL is as-
sociated with decreased mitochon-
drial DNA content in CC-RCC cells
(Meierhofer et al., 2004). This reduc-
tion in mitochondrial DNA is the result
of decreased mitochondrial mass that
results in decreased oxygen consump-
tion. Restoration of wild-type VHL in
these cells results in increased mito-
chondrial mass, indicating a regulatory
role for VHL in regulatingmitochondrial
biogenesis and respiration.
To date, the best-characterized role
of VHL is that as a negative regulator ofthe protein stability of the hypoxia-
inducible factor (HIF) family of tran-
scription factors. HIF has already
been shown to affect mitochondrial
respiration through the action of two
downstream targets, pyruvate dehy-
drogenase kinase (PDK-1) and cyto-
chrome oxidase (COX-4) (Fukuda
et al., 2007; Kim et al., 2006; Papan-
dreou et al., 2006). Mechanistically,
PDK-1 inhibits the conversion of pyru-
vate to acetyl-CoA, preventing pyru-
vate entry into the TCA cycle, while
COX-4 subunits determine the effi-
ciency of mitochondrial respiration in
response to different oxygen tensions.
Thus, past studies have already dem-
onstrated a key role for HIF in inhibiting
mitochondrial metabolism.
In contrast to HIF, the C-MYC onco-
gene promotes mitochondrial respira-
tion through increasing mitochondrial
biogenesis (Li et al., 2005). So how
do HIF and C-MYC work to regulate
mitochondrial biogenesis? Zhang
et al. (2007) found that disruption
of HIF activity in the VHL-defective
CC-RCC cells, through either a domi-
nant-negative HIF mutant or RNA
interference to the HIF-1a and HIF-2a
genes, resulted in increased mito-
chondrial mass, mtDNA content, and
increased oxygen consumption. Con-
versely, targeted disruption of
C-MYC expression in VHL-positive
cells resulted in diminished mitochon-
drial mass and oxygen consumption.
The authors identified a novel, direct
C-MYC target, PGC-1b, which is
downregulated by HIF. Silencing
PGC-1b resulted in decreased mito-
chondrial mass, further confirming
the role of C-MYC in mitochondrial
biogenesis.Developmental CeThe opposing effects of HIF and
C-MYC activities in the context of mi-
tochondrial biogenesis and function
suggest a complex process of regula-
tion to ensure efficient production of
ATP. HIF is able to regulate C-MYC ac-
tivity by directly modulating C-MYC
protein levels as well as inhibiting C-
MYC activity. HIF-mediated regulation
of C-MYC is in part due to the HIF-me-
diated induction of themyc-antagonist
MXI-1 (Corn et al., 2005). Interestingly,
Zhang and colleagues demonstrate
thatMXI-1 is a direct HIF target, finding
that MXI-1 is regulated by either HIF-1
or HIF-2 (Zhang et al., 2007). In addi-
tion, the authors find a novel role
for HIF in promoting C-MYC degrada-
tion through an MXI-1-independent
but proteasome-dependent manner.
Taken together, these findings delin-
eate several mechanisms of HIF in
counteracting C-MYC to regulate the
switch to aerobic glycolysis.
Zhang et al. (2007) characterized the
functional mechanism of HIF-medi-
ated inhibition of C-MYC activity in
the absence of wild-type VHL function.
It is unclear, however, if the same
mechanism of C-MYC regulation
functions to inhibit mitochondrial bio-
genesis under hypoxia. The authors
find upregulation of MXI-1 and down-
regulation of C-MYC protein levels un-
der hypoxic conditions, but the effect
of hypoxia on mitochondrial biogene-
sis and respiration was not character-
ized. Could chronic hypoxic exposure,
as found in the early stages of tumor
development, lead to the ‘‘irreversible’’
epigenetic shutdown of mitochondrial
respiration?
Interestingly, Zhang and colleagues
found that either HIF-1 or HIF-2 wasll 12, June 2007 ª2007 Elsevier Inc. 845
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PreviewsFigure 1. HIF Regulates Mitochondrial Function and Biogenesis
Inactivation of wild-type VHL function leads to the accumulation of the HIF-a subunit and the
subsequent dimerization with HIF-b, leading to activation of the HIF pathway. HIF activates tran-
scription of PDK1, which inhibits the conversion of pyruvate to acetyl-CoA by blocking the activity
of pyruvate dhydrogenase, which results in diminished mitochondrial respiration. MXI-1, another
HIF target, inhibits the transcriptional activity of C-MYC, while HIF also promotes the MXI-1-
independent proteasome-dependent degradation of C-MYC. HIF-mediated inhibition of C-MYC
thus results in reduced mitochondrial biogenesis.sufficient to counteract C-MYC ac-
tivity. In contrast, a recent report by
Gordan and colleagues suggested
that HIF-2a actually enhances C-
MYC transcriptional activity through
binding of Max, a C-MYC binding part-
ner, leading to an increase in cell prolif-
eration (Gordan et al., 2007).
In Warburg’s model of cancer
development, dysregulation of mito-
chondrial function is followed by an
upregulation of glycolysis. In the
model proposed by Zhang et al.846 Developmental Cell 12, June 2007 ª(2007), inappropriate activation of the
HIF pathway, a consequence of VHL
inactivation, results in the simulta-
neous downregulation of mitochon-
drial respiration and the activation of
aerobic glycolysis (Figure 1). The exact
contribution of the metabolic switch to
aerobic glycolysis to tumorigenesis re-
mains unclear, but the findings pre-
sented in the paper provide many
new molecular targets to dissect the
specific contributions of the inhibition
of mitochondrial biogenesis and aero-2007 Elsevier Inc.bic glycolysis. For example, it would
be interesting to examine if inhibition
of MXI-1 with RNA interference is suffi-
cient to block xenograft formation in
the presence of HIF-activation. While
Warburg downplayed the role of mu-
tation in cancer development and
emphasized the metabolic switch to
fermentation energy as critical for the
development of cancer, these novel
findings by Zhang and colleagues
may support this model at least in the
case of CC-RCC.
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